Genomic Characterization of Upper Tract Urothelial Carcinoma

Biochemistry, Genetics and Molecular Biology

• Prevalence 100%
• Next Generation Sequencing 100%
• HRAS 100%
• Genomics 100%
• Epigenetics 50%
• Gene Mutation 50%
• Somatic Mutation 50%
• Germline 50%
• Germ Cell 50%
• Mutated Genes 50%
• Mutation Rate 50%
• CDKN2B 50%
• ARID1A 50%
• Fibroblast Growth Factor Receptor 3 50%
• Biodiversity 50%

Keyphrases

• Upper Tract Urothelial Carcinoma 100%
• Genomic Characterization 100%
• Tumor 11%
• Genetic Modification 11%
• Tumor Protein p53 (TP53) 11%
• Copy number Variation 11%
• Next-generation Sequencing 11%
• High-grade Urothelial Carcinoma 11%
• Epigenetic Modification 5%
• Patient Management 5%
• Histologic 5%
• Statistical Analysis 5%
• Management Strategy 5%
• Mutation Pattern 5%
• Somatic mutation 5%
• Cancer Types 5%
• Measurement Analysis 5%
• Novel Therapies 5%
• Cancer Genes 5%
• Epidemiologic 5%
• Urothelial Carcinoma 5%
• Mutated Genes 5%
• Somatic Alterations 5%
• Fibroblast Growth Factor Receptor 3 (FGFR3) 5%
• Rare mutation 5%
• Tumor DNA 5%
• Germline DNA 5%
• Bladder Tumor 5%
• CDKN2B 5%
• Targeted Inhibitors 5%
• Mutation Frequency 5%
• ARID1A 5%
• Co-mutation 5%
• Biological Diversity 5%
• Targeted Panel 5%
• Potential Needs 5%
• Urothelial Bladder Cancer 5%
• Site-specific Management 5%

Medicine and Dentistry

• Transitional Cell Carcinoma 100%
• Bladder 26%
• Prevalence 10%
• Next Generation Sequencing 10%
• Tumor 10%
• Malignant Neoplasm 5%
• Neoplasm 5%
• Bladder Cancer 5%
• Outcome Assessment 5%
• Cancer Types 5%
• Somatics 5%
• Gene Mutation 5%
• Fibroblast Growth Factor Receptor 3 5%
• Somatic Mutation 5%
• Bladder Tumor 5%
• Mutation Rate 5%
• Biodiversity 5%
• Germ Cell 5%